Residency · Residency · Interventional Radiology

Percutaneous Transluminal Angioplasty: Principles and Technique

Historical Background and Principles

Percutaneous transluminal angioplasty was first described by Charles Dotter in 1964 using coaxial dilators, and Andreas Gruentzig introduced the balloon catheter in 1974. The mechanism of action is controlled intimal disruption and medial stretching to enlarge the vessel lumen. There is also the "Dotter effect," in which passage of wires and catheters alone can sometimes open stenotic lesions. PTA remains the foundation of endovascular therapy, and all other devices -- stents, atherectomy systems -- are adjuncts to or replacements for balloon angioplasty.

Balloon Catheter Design

Construction

Balloon catheters come in three compliance categories. Non-compliant balloons maintain a fixed diameter at rated burst pressure and are used for most peripheral applications. Semi-compliant balloons expand slightly beyond nominal diameter with increased pressure and are used in select scenarios. Compliant balloons show significant diameter change with pressure variation and are rarely used in peripheral work.

Key Specifications

The rated burst pressure (RBP) is the maximum pressure guaranteed by the manufacturer, typically 10 to 20 atmospheres. The nominal diameter is the balloon diameter at the labeled inflation pressure. The profile refers to the crossing diameter of the deflated balloon, with a lower profile improving crossability. Balloon length typically ranges from 2 to 22 cm, with longer balloons suited for diffuse disease and shorter ones for focal lesions.

Specialty Balloons

Scoring and cutting balloons contain atherotomes or wires on the balloon surface that create controlled plaque fracture, making them useful for resistant or recurrent stenoses. Drug-coated balloons (DCBs) are coated with paclitaxel to reduce neointimal hyperplasia. High-pressure balloons are rated to 20 to 30 atmospheres for calcified or fibrotic stenoses. Cryoplasty balloons use nitrous oxide to cool the vessel wall during dilation, but these have largely fallen out of use.

Patient Selection and Preprocedural Planning

Appropriate indications include symptomatic stenosis with hemodynamic significance, defined as greater than 50 percent diameter reduction with a pressure gradient or clinical correlation. Prior imaging such as CTA, MRA, or duplex ultrasound should be reviewed to understand lesion morphology, calcification, and runoff. The TASC classification guides expected success, with TASC A and B lesions having the best outcomes with PTA alone. An adequate anticoagulation plan and access site selection based on lesion location should be established before the procedure.

Technique

Access and Lesion Crossing

Appropriate arterial access is obtained based on the target -- antegrade femoral, retrograde femoral, or radial. Diagnostic angiography confirms lesion location, length, and severity. The reference vessel diameter and stenosis length are measured. The lesion is crossed with a guidewire, using hydrophilic wires for tight stenoses, with intraluminal crossing attempted first. Intraluminal wire position must be confirmed before balloon inflation.

Balloon Sizing

The balloon diameter should match the reference vessel diameter at a 1:1 ratio for most peripheral arteries. Oversizing increases the risk of dissection and perforation, while undersizing leads to inadequate dilation and early restenosis. The balloon length should cover the full lesion with slight overlap on either side, typically 1 to 2 cm beyond each end.

Inflation Protocol

Standard inflation involves gradual expansion to nominal pressure over 15 to 30 seconds. The inflation is held for 60 to 180 seconds, as prolonged inflations may improve acute results by allowing plaque remodeling. The balloon waist should be monitored: a persistent indentation indicates resistant disease, suggesting that a higher pressure, scoring balloon, or atherectomy may be needed. The balloon is deflated slowly and completely before repositioning, and completion angiography is performed after each inflation.

Endpoints of Successful Angioplasty

A successful angioplasty achieves less than 30 percent residual stenosis on angiography, no flow-limiting dissection, no significant pressure gradient (less than 5-10 mmHg mean translesional gradient), restored antegrade flow without significant delay, and improvement in distal runoff.

Complications

Dissection

Dissection is the most common complication of PTA. It is graded from Type A through F (adapted from the coronary classification). Types A through C represent minor intimal irregularity to extraluminal cap without flow limitation and are generally acceptable. Types D through F include spiral dissection, persistent filling defect, or flow-limiting dissection and require intervention such as prolonged balloon inflation or stenting. Flow-limiting dissection is the primary indication for provisional stenting.

Elastic Recoil

Elastic recoil is the immediate loss of luminal gain after balloon deflation. It is more common in heavily calcified and eccentric lesions and may necessitate stenting if recoil exceeds 30 to 50 percent of the gained diameter.

Perforation and Rupture

Risk factors include an oversized balloon, calcified vessel, and subintimal wire position. Perforations are classified as contained (extravasation without hemodynamic compromise) or free (active hemorrhage). Management includes prolonged balloon tamponade, covered stent placement, or coil embolization. Wire access across the perforation site must be maintained.

Distal Embolization

Plaque debris or thrombus can be dislodged during angioplasty. Treatment options include aspiration thrombectomy, catheter-directed thrombolysis, or distal embolectomy. Embolic protection devices should be considered in high-risk scenarios such as heavily ulcerated plaques.

Restenosis

Restenosis is the principal limitation of PTA, driven by neointimal hyperplasia. The femoropopliteal segment has the highest restenosis rates, at 40 to 60 percent at one year for PTA alone. Iliac PTA has much better long-term patency, exceeding 80 percent at 5 years for TASC A and B lesions.

Site-Specific Considerations

Iliac Arteries

The iliac arteries respond excellently to PTA, with primary patency of 70 to 90 percent at 5 years for focal lesions. Stenting is frequently used as a primary strategy (not just for bailout) given its superior outcomes. The kissing balloon technique is used for aortic bifurcation lesions.

Femoropopliteal Segment

The femoropopliteal segment is the most commonly treated segment in PAD but has higher restenosis rates due to its unique biomechanical environment, subject to flexion, compression, and torsion. Drug-coated balloons reduce restenosis by approximately 30 percent compared to plain balloon angioplasty. Stenting should be considered only for a suboptimal PTA result, such as flow-limiting dissection or greater than 30 percent recoil.

Infrapopliteal Arteries

PTA is the primary endovascular treatment below the knee, as stenting data is limited in this territory. Small vessel size increases technical difficulty. The goal is straight-line flow to the foot, ideally to the angiosome supplying the wound. Long-term patency is poor, but limb salvage rates are acceptable because the vessel often only needs to remain open until wound healing occurs.

Drug-Coated Balloons: The Evolving Landscape

Paclitaxel inhibits smooth muscle cell proliferation and neointimal hyperplasia. The IN.PACT Admiral and Lutonix trials demonstrated improved patency over uncoated balloons in femoropopliteal disease. The 2018 Katsanos meta-analysis raised concerns about a late mortality signal with paclitaxel devices, leading to an FDA review. However, subsequent larger analyses and patient-level data did not confirm increased mortality. Proposed mechanisms such as paclitaxel embolization and systemic absorption were not supported by pharmacokinetic data. DCBs remain widely used, with ongoing long-term surveillance continuing.

<image>Sequential illustration of percutaneous transluminal angioplasty technique. Four panels showing: (1) Guidewire crossing a stenotic iliac artery lesion with a diagnostic catheter proximal to the lesion; (2) Balloon catheter positioned across the stenosis with the deflated balloon spanning the full lesion length; (3) Balloon inflated showing a waist at the site of maximum stenosis that gradually disappears with full inflation; (4) Post-angioplasty result with restored luminal diameter and minor intimal irregularity. Labels indicate reference vessel diameter, lesion length, and balloon sizing ratio.</image>

<image>Classification of post-angioplasty dissections in peripheral arteries. Six panels (Types A through F) showing cross-sectional and longitudinal views: Type A shows minor intimal flap; Type B shows larger linear dissection; Type C shows extraluminal cap without flow impairment; Type D shows spiral dissection; Type E shows persistent contrast-filled dissection with reduced flow; Type F shows total occlusion from dissection. Types A-C are labeled as acceptable, Types D-F as requiring intervention with stenting.</image>

<image>Comparison of plain balloon angioplasty versus drug-coated balloon angioplasty in the superficial femoral artery. Split-panel illustration showing: Left panel - standard PTA with immediate good result but cross-sectional inset at 12 months demonstrating neointimal hyperplasia causing restenosis; Right panel - DCB angioplasty with paclitaxel transfer to the vessel wall shown as a highlighted zone, and cross-sectional inset at 12 months showing preserved lumen with minimal neointimal hyperplasia. A bar graph below compares 12-month primary patency rates (approximately 55-65% for plain balloon versus 75-85% for DCB).</image>

Clinical Pearls

The guiding principle is to start with the least aggressive treatment -- PTA first, then stent only if the result is suboptimal. This provisional stenting strategy is standard in the femoropopliteal segment. A persistent balloon waist that does not efface at nominal pressure indicates heavily calcified or fibrotic disease, and the operator should consider a scoring balloon or atherectomy before repeated high-pressure inflations that risk perforation.

In the iliac arteries, primary stenting is acceptable and often preferred given the excellent long-term results. Below the knee, PTA is the workhorse, and operators should not chase a perfect angiographic result -- adequate inline flow for wound healing is the goal. Distal embolization should always be checked for after PTA with runoff angiography.

The paclitaxel mortality controversy has not been substantiated by large patient-level analyses, but awareness of the debate is important for informed consent discussions.

References

• Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Circulation 1964
• Gruentzig A, Hopff H. Percutaneous recanalization after chronic arterial occlusion with a new dilator-catheter. Dtsch Med Wochenschr 1974
• Rosenfield K et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease (IN.PACT SFA). N Engl J Med 2015
• Katsanos K et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis. J Am Heart Assoc 2018
• Nordanstig J et al. Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of PAD

Read this lecture as Markdown